Artykuły w czasopismach na temat „Caleb T”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Caleb T”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Whitlark, Jason. "Listen, Understand, Obey: Essays on Hebrews in Honor of Gareth Lee Cockerill ed. by Caleb T. Friedman". Catholic Biblical Quarterly 82, nr 1 (2020): 164–65. http://dx.doi.org/10.1353/cbq.2020.0040.
Pełny tekst źródłaBorker, Parth, Yi Bao, Yuanyuan Qiao, Arul Chinnaiyan, Jae Eun Choi, Yuping Zhang, Rahul Mannan i in. "Abstract 7479: Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy". Cancer Research 84, nr 6_Supplement (22.03.2024): 7479. http://dx.doi.org/10.1158/1538-7445.am2024-7479.
Pełny tekst źródłaLiu, Vincent, Katalin Sandor, Bence Daniel, Lionel Berthoin, Shan Sabri, Sofia Panagiotopoulou, Yajie Yin i in. "Abstract 1701: Single-cell multi-omic profiling and clonal tracing of the human gynecological tumor microenvironment". Cancer Research 82, nr 12_Supplement (15.06.2022): 1701. http://dx.doi.org/10.1158/1538-7445.am2022-1701.
Pełny tekst źródłaHurvitz, Sara, Sung-Bae Kim, Wei-Pang Chung, Seock-Ah Im, Yeon Hee Park, Roberto Hegg, Min-Hwan Kim i in. "Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03". Cancer Research 82, nr 4_Supplement (15.02.2022): GS3–01—GS3–01. http://dx.doi.org/10.1158/1538-7445.sabcs21-gs3-01.
Pełny tekst źródłaFan, Zenghua, David Y. Oh, Anthony Wong, Katsuto Shinohara, Hao Nguyen, Caleb Hwang, Hewitt Chang i in. "Abstract 4988: Responders to combination radiation and PD-1 blockade demonstrate reduced myeloid immunosuppression and enhanced interferon signaling in oligometastatic prostate cancer patients". Cancer Research 84, nr 6_Supplement (22.03.2024): 4988. http://dx.doi.org/10.1158/1538-7445.am2024-4988.
Pełny tekst źródłaLafargue, Audrey M., Hailun Wang, Sivarajan T. Chettiar, Rajendra P. Gajula, Amol C. Shetty, Yang Song, Brian W. Simons i in. "Abstract 2968: TWIST1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of TWIST1". Cancer Research 84, nr 6_Supplement (22.03.2024): 2968. http://dx.doi.org/10.1158/1538-7445.am2024-2968.
Pełny tekst źródłaTien, Jean C., Yu Chang, Yuping Zhang, Jonathan Chou, Yunhui Cheng, Xiaoju Wang, Jianzhang Yang i in. "Abstract PR010: CDK12 loss promotes prostate cancer development while exposing vulnerabilities to paralog-based synthetic lethality". Molecular Cancer Therapeutics 23, nr 6_Supplement (10.06.2024): PR010. http://dx.doi.org/10.1158/1538-8514.synthleth24-pr010.
Pełny tekst źródłaDai, Chaobin, Bin Zhang, Yunyang Liao, Qicai Liu, Feiguang Wu, Xiaoting Lv, Kai Zeng i Xiaofeng Zhu. "CALCB rs3829222 T/T Genotype and Low Expression of CALCB Are High-Risk Factors for Adenoid Cystic Carcinoma of Salivary Gland". Disease Markers 2021 (12.06.2021): 1–5. http://dx.doi.org/10.1155/2021/5546858.
Pełny tekst źródłaBUENO, VINICIUS R., MORGAN R. GOSTEL i GUSTAVO HEIDEN. "The spiraling story of Tyleropappus and a new name for Calea (Asteraceae: Neurolaeneae) from Venezuela". Phytotaxa 622, nr 1 (24.10.2023): 75–84. http://dx.doi.org/10.11646/phytotaxa.622.1.5.
Pełny tekst źródłaAlkashgari, Hossam, Cornelia Stoian, Caleb Ruiz-Jimenez, Jacqueline Coats, Carlos A. Casiano, Sinisa Dovat i Kimberly J. Payne. "Abstract 1528: Molecular mechanisms of TSLP as a therapy for CRLF2 B-Cell acute lymphoblastic leukemia". Cancer Research 82, nr 12_Supplement (15.06.2022): 1528. http://dx.doi.org/10.1158/1538-7445.am2022-1528.
Pełny tekst źródłaMuffly, Lori, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S. Advani, Selina M. Luger i in. "Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia". Blood Advances 6, nr 14 (15.07.2022): 4085–92. http://dx.doi.org/10.1182/bloodadvances.2022007197.
Pełny tekst źródłaEston, Roger G., Gaynor Parfitt, Laura Campbell i Kevin L. Lamb. "Reliability of Effort Perception for Regulating Exercise Intensity in Children Using the Cart and Load Effort Rating (CALER) Scale". Pediatric Exercise Science 12, nr 4 (listopad 2000): 388–97. http://dx.doi.org/10.1123/pes.12.4.388.
Pełny tekst źródłaKaufman, P. A., G. Broadwater, K. Lezon-Geyda, L. G. Dressler, D. Berry, P. Friedman, E. P. Winer i in. "CALGB 150002: Correlation of HER2 and chromosome 17 (ch17) copy number with trastuzumab (T) efficacy in CALGB 9840, paclitaxel (P) with or without T in HER2+ and HER2- metastatic breast cancer (MBC)". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 1009. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.1009.
Pełny tekst źródłaHayes, D. F., A. Thor, L. Dressler, D. Weaver, G. Broadwater, L. Goldstein, S. Martino, J. Ingle, I. C. Henderson i D. Berry. "HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 510. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.510.
Pełny tekst źródłaMrózek, Krzysztof, Andrew J. Carroll, Kati Maharry, Kathleen W. Rao, Shivanand R. Patil, Mark J. Pettenati, Michael S. Watson i in. "Central Review of Cytogenetics Is Essential for Cooperative Group Clinical and Correlative Studies of Acute Leukemia: The Cancer and Leukemia Group B (CALGB) 8461 Experience." Blood 104, nr 11 (16.11.2004): 1081. http://dx.doi.org/10.1182/blood.v104.11.1081.1081.
Pełny tekst źródłaGajewski, T. F., D. Niedzwiecki, J. Johnson, G. Linette, C. Bucher, M. Blaskovich, S. Sebti i F. Haluska. "Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 8014. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.8014.
Pełny tekst źródłaLozanski, Gerard, Ben Sanford, Krzysztof Mrozek, Colin Edwards, Rebecca Pearson, Clara D. Bloomfield, Richard A. Larson i Wendy Stock. "Quantitative Measurement of CD52 Expression and Alemtuzumab Binding in Adult Acute Lymphoblastic Leukemia (ALL): Correlation with Immunophenotype and Cytogenetics in Patients (Pts) Enrolled on a Phase I/II Trial from the Cancer and Leukemia Group B (CALGB 10102)." Blood 110, nr 11 (16.11.2007): 2386. http://dx.doi.org/10.1182/blood.v110.11.2386.2386.
Pełny tekst źródłaGiordano, S. H., Z. Duan, Y. F. Kuo, G. N. Hortobagyi, J. Freeman i J. S. Goodwin. "The impact of CALGB 9344 on adjuvant taxane (T) Use for breast cancer (BC)". Journal of Clinical Oncology 23, nr 16_suppl (czerwiec 2005): 669. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.669.
Pełny tekst źródłaWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Bercedis L. Peterson, John G. Gribben, Vicki A. Morrison, Kanti R. Rai, Richard A. Larson i John C. Byrd. "Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712". Journal of Clinical Oncology 29, nr 10 (1.04.2011): 1349–55. http://dx.doi.org/10.1200/jco.2010.31.1811.
Pełny tekst źródłaStradomska, Dominika, Monika Heba, Aleksandra Czernek, Nikodem Kuźnik, Danuta Gillner, Katarzyna Maresz, Wojciech Pudło, Andrzej Jarzębski i Katarzyna Szymańska. "Lipase Immobilized on MCFs as Biocatalysts for Kinetic and Dynamic Kinetic Resolution of sec-Alcohols". Catalysts 11, nr 4 (20.04.2021): 518. http://dx.doi.org/10.3390/catal11040518.
Pełny tekst źródłaMiura, D., Y. Saitoh, T. Iwatani, H. Kawabata i N. Inoshita. "Chromosome enumeration probe 17 (CEP) ratio to predict chemosensitivity in HER-2 overexpressing breast cancer". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): e11600-e11600. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e11600.
Pełny tekst źródłaCzuczman, Myron S., Pierluigi Porcu, Jeffrey Johnson, Donna Niedzwiecki, Michael Kelly, Eric D. Hsi, James R. Cook, George Canellos, Bruce D. Cheson i For the Cancer and Leukemia Group B. "Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901". Leukemia & Lymphoma 48, nr 1 (styczeń 2007): 97–103. http://dx.doi.org/10.1080/10428190600961058.
Pełny tekst źródłaRaychaudhuri, Suravi, Ilana Yurkiewicz, Gabriel N. Mannis, Bruno C. Medeiros, Steve E. Coutre, Lori S. Muffly i Michaela Liedtke. "Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403." Journal of Clinical Oncology 39, nr 15_suppl (20.05.2021): e19005-e19005. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e19005.
Pełny tekst źródłaBaer, Maria R., Carleton C. Stewart, David Lawrence, Diane C. Arthur, John C. Byrd, Frederick R. Davey, Charles A. Schiffer i Clara D. Bloomfield. "Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)". Blood 90, nr 4 (15.08.1997): 1643–48. http://dx.doi.org/10.1182/blood.v90.4.1643.
Pełny tekst źródłaBaer, Maria R., Carleton C. Stewart, David Lawrence, Diane C. Arthur, John C. Byrd, Frederick R. Davey, Charles A. Schiffer i Clara D. Bloomfield. "Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)". Blood 90, nr 4 (15.08.1997): 1643–48. http://dx.doi.org/10.1182/blood.v90.4.1643.1643_1643_1648.
Pełny tekst źródłaWoyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Bercedis Peterson, John G. Gribben, Vicki A. Morrison, Kanti R. Rai, Richard A. Larson i John C. Byrd. "Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712." Blood 114, nr 22 (20.11.2009): 539. http://dx.doi.org/10.1182/blood.v114.22.539.539.
Pełny tekst źródłaCzuczman, Myron S., Pierluigi Porcu, Jeff Johnson, Donna Niedzwiecki, George P. Canellos i Bruce D. Cheson. "CALGB 59901: Results of a Phase II Study of 506U78 in CTCL and PTCL." Blood 104, nr 11 (16.11.2004): 2486. http://dx.doi.org/10.1182/blood.v104.11.2486.2486.
Pełny tekst źródłaFobare, Sydney, Jessica Kohlschmidt, Hatice Gulcin Ozer, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Ramiro Garzon i in. "Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia". Blood Advances 6, nr 5 (25.02.2022): 1371–80. http://dx.doi.org/10.1182/bloodadvances.2021006242.
Pełny tekst źródłaPeñaloza De La Torre, Ulises, i Gabriela Condori Condori. "Efecto antibacteriano del paramonoclorofenol alcanforado vs la asociación de hidróxido de calcioparamonoclorofenol alcanforado, sobre el cultivo in vitro de enterococcus faecalis". Revista Médica Basadrina 10, nr 1 (8.05.2019): 16–19. http://dx.doi.org/10.33326/26176068.2016.1.590.
Pełny tekst źródłaHylton, N., J. Blume, C. Gatsonis, R. Gomez, W. Bernreuter, E. Pisano, M. Rosen, H. Marques, L. Esserman i M. Schnall. "MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007". Journal of Clinical Oncology 27, nr 15_suppl (20.05.2009): 529. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.529.
Pełny tekst źródłaVenook, Alan P., Donna Niedzwiecki, Margarita Lopatin, Xing Ye, Mark Lee, Paula N. Friedman, Wendy Frankel i in. "Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581". Journal of Clinical Oncology 31, nr 14 (10.05.2013): 1775–81. http://dx.doi.org/10.1200/jco.2012.45.1096.
Pełny tekst źródłaNurhablisyah, Nurhablisyah, i Khikmah Susanti. "Analisis Pesan Visual pada Media Kampanye Luar Ruang Caleg 2019". Magenta | Official Journal STMK Trisakti 3, nr 02 (26.07.2019): 478–86. http://dx.doi.org/10.61344/magenta.v3i02.49.
Pełny tekst źródłaRodrigues, William Costa, i Paulo Cesar Rodrigues Cassino. "Parasitóides Associados a Cochonilhas e Aleirodídeos (Sternorrhyncha) de Plantas Cítricas no Estado do Rio de Janeiro". EntomoBrasilis 5, nr 1 (21.03.2012): 33–36. http://dx.doi.org/10.12741/ebrasilis.v5i1.177.
Pełny tekst źródłaSilverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, Richard M. Stone, Bayard L. Powell, Christy Mayo, Jay T. Backstrom i Richard A. Larson. "Response Rates in Patients with Acute Myeloid Leukemia (AML), Treated with Azacitidine, Using WHO and International Working Group (IWG) Criteria for Myelodysplastic Syndrome (MDS)." Blood 106, nr 11 (16.11.2005): 1848. http://dx.doi.org/10.1182/blood.v106.11.1848.1848.
Pełny tekst źródłaStock, Wendy, Jeffrey Johnson, Daohai Yu, Diane Bennett, Dorie Sher, Richard M. Stone, Jonathan E. Kolitz i in. "Daunorubicin Dose Intensification during Treatment of Adult Acute Lymphoblastic Leukemia (ALL): Final Results from Cancer and Leukemia Group B Study 19802." Blood 106, nr 11 (16.11.2005): 1833. http://dx.doi.org/10.1182/blood.v106.11.1833.1833.
Pełny tekst źródłaMarcucci, Guido, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum i in. "Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801". Blood Advances 4, nr 4 (24.02.2020): 696–705. http://dx.doi.org/10.1182/bloodadvances.2019000492.
Pełny tekst źródłaBattaglin, Francesca, Yasmine Baca, Joshua Millstein, Yan Yang, Joanne Xiu, Hiroyuki Arai, Jingyuan Wang i in. "CCR5andCCL5gene expression in colorectal cancer: comprehensive profiling and clinical value". Journal for ImmunoTherapy of Cancer 12, nr 1 (styczeń 2024): e007939. http://dx.doi.org/10.1136/jitc-2023-007939.
Pełny tekst źródłaBlum, William, Ben Sanford, Rebecca B. Klisovic, Daniel J. DeAngelo, Geoffrey Uy, Bayard L. Powell, Wendy Stock i in. "Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)". Blood 120, nr 21 (16.11.2012): 44. http://dx.doi.org/10.1182/blood.v120.21.44.44.
Pełny tekst źródłaMarcucci, Guido, K. Mrózek, A. S. Ruppert, K. Maharry, J. E. Kolitz, R. J. Mayer, M. J. Pettenati i in. "t(8;21) Acute Myeloid Leukemia (AML) Differs from inv(16) AML in Pretreatment Characteristics, Outcome and Prognostic Factors Predicting Outcome: A Cancer and Leukemia Group B (CALGB) Study." Blood 104, nr 11 (16.11.2004): 2017. http://dx.doi.org/10.1182/blood.v104.11.2017.2017.
Pełny tekst źródłaLozanski, Gerard, Ben Sanford, Daohai Yu, Rebecca Pearson, Colin Edwards, John C. Byrd, Richard A. Larson, Clara D. Bloomfield i Wendy Stock. "CD52 Expression in Adult Acute Lymphoblastic Leukemia (ALL): Quantitative Flow Cytometry Provides New Insights." Blood 108, nr 11 (1.11.2006): 2293. http://dx.doi.org/10.1182/blood.v108.11.2293.2293.
Pełny tekst źródłaWilson, E., J. Crown, J. Ballot, D. McDonnell, E. Sheehan i J. Healy. "Estimating the real cost of adjuvant (A) trastuxumab (T) in patients(pts) with HER-2+ (H+) early stage breast cancer (ESBC)". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 6081. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.6081.
Pełny tekst źródłaDemichelis, Roberta, Karla Adriana Espinosa, Juan Rangel-Patiño, Emmanuel Almanza i Ana Cooke. "Pediatric-Inspired Regimens Are Associated with Better Outcomes When Compared with Hypercvad in Hispanic Adolescents and Young Adults with Acute Lymphoblastic Leukemia". Blood 134, Supplement_1 (13.11.2019): 3877. http://dx.doi.org/10.1182/blood-2019-125370.
Pełny tekst źródłaHarpole, D. H., R. Petersen, S. Mukherjee, A. Bild, H. Dressman, R. Kratzke, M. J. Kelley i in. "A genomic strategy to refine prognosis in early stage non-small cell lung carcinoma (NSCLC)". Journal of Clinical Oncology 24, nr 18_suppl (20.06.2006): 7026. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7026.
Pełny tekst źródłaBashey, Asad, Kouros Owzar, Jeffrey L. Johnson, Steven M. Devine, Richard K. Shadduck, Thomas C. Shea i Charles Linker. "Reduced-Intensity Allogeneic Transplantation after Failure of Autologous Transplantation: A Prospective Multi-Center CALGB Study." Blood 108, nr 11 (16.11.2006): 3122. http://dx.doi.org/10.1182/blood.v108.11.3122.3122.
Pełny tekst źródłaMuffly, Lori, Jun Yin, Sawyer Jacobson, Anjali Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow i in. "Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data". Blood 138, Supplement 1 (5.11.2021): 337. http://dx.doi.org/10.1182/blood-2021-148804.
Pełny tekst źródłaRyan, Charles J., Sandipan Dutta, William Kevin Kelly, Rob Middleberg, Carly Russell, Eric Jay Small, Michael J. Morris, Mary-Ellen Taplin i Susan Halabi. "Serum androgens and survival in metastatic castration resistant prostate cancer (mCRPC) patients treated with docetaxel and prednisone: Results from CALGB 90401 (Alliance)." Journal of Clinical Oncology 35, nr 15_suppl (20.05.2017): 5067. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5067.
Pełny tekst źródłaMalnassy, Greg, Susan Geyer, Noreen Fulton, Greg Koval, Donna Niedzwiecki, Victoria Carlton, Li Weng i in. "Comparison Of Deep Sequencing and Allele-Specific Oligonucleotide PCR Methods For MRD Quantitation In Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma: CALGB 10403 and CALGB 59909 (Alliance)". Blood 122, nr 21 (15.11.2013): 2547. http://dx.doi.org/10.1182/blood.v122.21.2547.2547.
Pełny tekst źródłaPaschka, P., M. D. Radmacher, G. Marcucci, A. S. Ruppert, T. Vukosavljevic, S. P. Whitman, K. Mrózek, C. Liu, R. A. Larson i C. D. Bloomfield. "Outcome prediction in adult core binding factor (CBF) acute myeloid leukemia (AML) with gene expression profiling: A Cancer and Leukemia Group B (CALGB) study". Journal of Clinical Oncology 25, nr 18_suppl (20.06.2007): 7011. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7011.
Pełny tekst źródłaSilverman, Lewis R., David R. McKenzie, Bercedis L. Peterson, Erin P. Demakos, Neil T. Malone, James F. Holland i Richard A. Larson. "Azacitidine Prolongs Survival and Time to AML Transformation in High-Risk Myelodysplastic Syndrome (MDS) Patients ≥ 65 Years of Age." Blood 106, nr 11 (16.11.2005): 2524. http://dx.doi.org/10.1182/blood.v106.11.2524.2524.
Pełny tekst źródłaKhan, Abdul Moiz, Kyle Kondrat, Aditi Sharma i Jay Yang. "A Single Center, 10-Year Experience of CALGB-10403 Regimen in AYA Population with Philadelphia-Chromosome Negative Acute Lymphoblastic Leukemia". Blood 142, Supplement 1 (28.11.2023): 5822. http://dx.doi.org/10.1182/blood-2023-186830.
Pełny tekst źródła